TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2009

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Teri N Kreisl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.